Evidence map›Paper›PMID 42780190›Full record

ArticleFrontiers in oncology2026

The therapy-conditioned host: a state-transition framework for second primary cancer evolution.

Rosiane Batista Mastelari, Tiago Veiras Collares

Abstract read
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Rosiane Batista MastelariUniversity Hospital, Federal University of Pelotas - HUBrasil, Pelotas, Brazil.
Tiago Veiras CollaresUniversity Hospital, Federal University of Pelotas - HUBrasil, Pelotas, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Second primary cancers (SPCs) are an important challenge in cancer survivorship, yet their heterogeneous biological origins cannot be reduced to treatment exposure. Inherited susceptibility shared environmental and tissue-field effects, ageing, pre-existing somatic mosaicism and treatment-associated mutagenesis contribute to SPC risk. High-resolution studies show that therapy can alter somatic selection, clonal architecture and persistent immune or stromal states in normal tissues. We propose the therapy-conditioned host as a State-Transition framework integrating these observations in survivorship. In this framework, a pre-treatment host state (H

Indexed as

cancer interceptioncancer survivorshipclonal hematopoiesisclonal selectionsecond primary cancersomatic evolutiontherapy-related mutagenesistissue ecology

Identifiers

PMID42780190
PMCPMC13597459

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.